JP2003511007A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003511007A5 JP2003511007A5 JP2000588352A JP2000588352A JP2003511007A5 JP 2003511007 A5 JP2003511007 A5 JP 2003511007A5 JP 2000588352 A JP2000588352 A JP 2000588352A JP 2000588352 A JP2000588352 A JP 2000588352A JP 2003511007 A5 JP2003511007 A5 JP 2003511007A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- protein
- seq
- binding
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 description 42
- 102000004169 proteins and genes Human genes 0.000 description 31
- 108090000623 proteins and genes Proteins 0.000 description 31
- 238000000034 method Methods 0.000 description 27
- 239000002773 nucleotide Substances 0.000 description 27
- 125000003729 nucleotide group Chemical group 0.000 description 27
- 125000003275 alpha amino acid group Chemical group 0.000 description 21
- 150000001413 amino acids Chemical class 0.000 description 14
- 239000002157 polynucleotide Substances 0.000 description 13
- 102000040430 polynucleotide Human genes 0.000 description 13
- 108091033319 polynucleotide Proteins 0.000 description 13
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 12
- 239000012634 fragment Substances 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 9
- 102100020791 Interleukin-13 receptor subunit alpha-1 Human genes 0.000 description 8
- 101710112663 Interleukin-13 receptor subunit alpha-1 Proteins 0.000 description 8
- 102000004559 Interleukin-13 Receptors Human genes 0.000 description 7
- 108010017511 Interleukin-13 Receptors Proteins 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 102100020793 Interleukin-13 receptor subunit alpha-2 Human genes 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 108040003607 interleukin-13 receptor activity proteins Proteins 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 206010027654 Allergic conditions Diseases 0.000 description 2
- 206010003645 Atopy Diseases 0.000 description 2
- 208000023328 Basedow disease Diseases 0.000 description 2
- 208000015023 Graves' disease Diseases 0.000 description 2
- 208000024781 Immune Complex disease Diseases 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 201000009961 allergic asthma Diseases 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 208000024326 hypersensitivity reaction type III disease Diseases 0.000 description 2
- 206010025135 lupus erythematosus Diseases 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 201000008383 nephritis Diseases 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 206010043778 thyroiditis Diseases 0.000 description 2
- 208000025883 type III hypersensitivity disease Diseases 0.000 description 2
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21133598A | 1998-12-14 | 1998-12-14 | |
| US09/211,335 | 1998-12-14 | ||
| PCT/US1999/029493 WO2000036103A1 (en) | 1998-12-14 | 1999-12-13 | Cytokine receptor chain |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010097430A Division JP2010263889A (ja) | 1998-12-14 | 2010-04-20 | サイトカインレセプター鎖 |
| JP2014025113A Division JP2014113165A (ja) | 1998-12-14 | 2014-02-13 | サイトカインレセプター鎖 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2003511007A JP2003511007A (ja) | 2003-03-25 |
| JP2003511007A5 true JP2003511007A5 (enExample) | 2007-02-01 |
| JP5519087B2 JP5519087B2 (ja) | 2014-06-11 |
Family
ID=22786499
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000588352A Expired - Fee Related JP5519087B2 (ja) | 1998-12-14 | 1999-12-13 | サイトカインレセプター鎖 |
| JP2010097430A Pending JP2010263889A (ja) | 1998-12-14 | 2010-04-20 | サイトカインレセプター鎖 |
| JP2014025113A Withdrawn JP2014113165A (ja) | 1998-12-14 | 2014-02-13 | サイトカインレセプター鎖 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010097430A Pending JP2010263889A (ja) | 1998-12-14 | 2010-04-20 | サイトカインレセプター鎖 |
| JP2014025113A Withdrawn JP2014113165A (ja) | 1998-12-14 | 2014-02-13 | サイトカインレセプター鎖 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US7507706B1 (enExample) |
| EP (1) | EP1141286B1 (enExample) |
| JP (3) | JP5519087B2 (enExample) |
| CN (2) | CN1352686A (enExample) |
| AT (1) | ATE342976T1 (enExample) |
| AU (1) | AU780031B2 (enExample) |
| BR (1) | BR9916209A (enExample) |
| CA (1) | CA2356779C (enExample) |
| CY (1) | CY1107657T1 (enExample) |
| DE (1) | DE69933696T2 (enExample) |
| DK (1) | DK1141286T3 (enExample) |
| ES (1) | ES2277460T3 (enExample) |
| MX (1) | MXPA01006006A (enExample) |
| NZ (1) | NZ512942A (enExample) |
| PT (1) | PT1141286E (enExample) |
| WO (1) | WO2000036103A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7553487B2 (en) | 1998-12-14 | 2009-06-30 | Genetics Institute, Llc | Method and compositions for treating asthma |
| US7507706B1 (en) | 1998-12-14 | 2009-03-24 | Genetics Institute, Llc | Cytokine receptor chain |
| EP1333850B1 (en) * | 2000-10-20 | 2008-08-20 | Genetics Institute, Inc. | Use of il-13 inhibitors for the treatment of tumors |
| JP2006516035A (ja) * | 2003-01-17 | 2006-06-15 | チルドレンズ ホスピタル メディカル センター | アレルギー治療におけるｔｆｆ２、またはｔｆｆ２誘導剤の使用 |
| US20040198686A1 (en) * | 2003-01-18 | 2004-10-07 | Rothenberg Marc Elliot | Regulation of allergen induced gene |
| EP1444989A1 (en) | 2003-02-07 | 2004-08-11 | Giorgio Dr. Stassi | Sensitizing cells for apoptosis by selectively blocking cytokines |
| WO2004092404A2 (en) * | 2003-04-11 | 2004-10-28 | Wyeth | Inhibitors of acidic mammalian chitinase as asthma therapeutics |
| GB0407315D0 (en) | 2003-07-15 | 2004-05-05 | Cambridge Antibody Tech | Human antibody molecules |
| MX361174B (es) | 2003-12-23 | 2018-11-29 | Genentech Inc | Anticuerpos anti-il13 novedosos y sus usos. |
| US20070178520A1 (en) * | 2004-02-27 | 2007-08-02 | Barbara Wolff-Winiski | Screening assay for modulators of interaction between interleukin-12 and/or -23 with their receptors |
| AR049390A1 (es) * | 2004-06-09 | 2006-07-26 | Wyeth Corp | Anticuerpos contra la interleuquina-13 humana y usos de los mismos |
| US7501121B2 (en) * | 2004-06-17 | 2009-03-10 | Wyeth | IL-13 binding agents |
| US20090098142A1 (en) * | 2004-06-09 | 2009-04-16 | Kasaian Marion T | Methods and compositions for treating and monitoring treatment of IL-13-associated disorders |
| WO2006055638A2 (en) | 2004-11-17 | 2006-05-26 | Abgenix, Inc. | Fully human monoclonal antibodies to il-13 |
| EP2532677A1 (en) | 2005-10-21 | 2012-12-12 | Novartis AG | Human antibodies against il13 and therapeutic uses |
| US20090068195A1 (en) * | 2007-04-23 | 2009-03-12 | Wyeth | Methods and compositions for treating and monitoring treatment of il-13-associated disorders |
| WO2008153790A2 (en) * | 2007-05-29 | 2008-12-18 | University Of Cincinnati | Methods of modulating inflammation and compositions therefore |
| MX2016001854A (es) | 2013-08-12 | 2016-09-06 | Genentech Inc | Composiciones y metodo para tratar condiciones asociadas con el complemento. |
| SG11201601823TA (en) | 2013-09-13 | 2016-04-28 | Genentech Inc | Methods and compositions comprising purified recombinant polypeptides |
| PL3044323T3 (pl) | 2013-09-13 | 2022-06-27 | F.Hoffmann-La Roche Ag | Sposoby wykrywania i ilościowego oznaczania białka komórki gospodarza w liniach komórkowych |
| JP7657548B2 (ja) | 2017-04-21 | 2025-04-07 | エランコ・ユーエス・インコーポレイテッド | 獣医学的使用のためのｉｌ４／ｉｌ１３受容体分子 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| WO1989004838A1 (en) | 1987-11-25 | 1989-06-01 | Immunex Corporation | Interleukin-1 receptors |
| US5359037A (en) | 1988-09-12 | 1994-10-25 | Yeda Research And Development Co. Ltd. | Antibodies to TNF binding protein I |
| WO1990005183A1 (en) | 1988-10-31 | 1990-05-17 | Immunex Corporation | Interleukin-4 receptors |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5011778A (en) | 1989-05-23 | 1991-04-30 | Otsuka Pharmaceutical Co., Ltd. | Monoclonal antibodies directed to IL-1 activated endothelial cells and medicaments employing the monoclonal antibodies |
| WO1991009059A1 (en) | 1989-12-20 | 1991-06-27 | Schering Corporation | Antibody antagonists of human interleukin-4 |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5246701A (en) | 1990-10-05 | 1993-09-21 | Ludwig Institute For Cancer Research | Method for inhibiting production of IgE by using IL-9 inhibitors |
| HU217099B (hu) | 1991-03-29 | 1999-11-29 | Elf Sanofi Sa. | Eljárás citokin típusú aktivitással rendelkező fehérje, azt kódoló rekombináns DNS-szekvencia és a megfelelő transzformált sejtek és mikroorganizmusok előállítására |
| AU3658093A (en) | 1992-02-10 | 1993-09-03 | Seragen, Inc. | Desensitization to specific allergens |
| US5397703A (en) | 1992-07-09 | 1995-03-14 | Cetus Oncology Corporation | Method for generation of antibodies to cell surface molecules |
| US5596072A (en) | 1992-08-21 | 1997-01-21 | Schering Corporation | Method of refolding human IL-13 |
| EP0656947A1 (en) | 1992-08-21 | 1995-06-14 | Schering Corporation | Human interleukin-13 |
| EP0604693A1 (en) | 1992-12-29 | 1994-07-06 | Schering-Plough | Monoclonal antibodies against the human interleukin-4 receptor and hybridomas producing the same |
| CN1127351C (zh) | 1993-09-02 | 2003-11-12 | 达特茅斯学院理事 | 诱导抗原特异性ｔ细胞耐受的方法 |
| EP0659766A1 (en) | 1993-11-23 | 1995-06-28 | Schering-Plough | Human monoclonal antibodies against human cytokines and methods of making and using such antibodies |
| GB9415379D0 (en) | 1994-07-29 | 1994-09-21 | Smithkline Beecham Plc | Novel compounds |
| US5696234A (en) | 1994-08-01 | 1997-12-09 | Schering Corporation | Muteins of mammalian cytokine interleukin-13 |
| US5705154A (en) | 1995-03-08 | 1998-01-06 | Schering Corporation | Humanized monoclonal antibodies against human interleukin-4 |
| ES2334408T3 (es) | 1995-10-23 | 2010-03-09 | Zenyth Operations Pty Ltd | Receptor de hematopoyetina y secuencias geneticas que lo codifican. |
| FR2742156A1 (fr) * | 1995-12-06 | 1997-06-13 | Sanofi Sa | Polypeptide recepteur de l'il-13 |
| ATE239041T1 (de) | 1996-02-09 | 2003-05-15 | Basf Ag | Humane antikörper welche an humanen tnfalpha binden |
| US6664227B1 (en) | 1996-03-01 | 2003-12-16 | Genetics Institute, Llc | Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains |
| US5710023A (en) * | 1996-03-01 | 1998-01-20 | Genetics Institute, Inc. | IL-13 cytokine receptor chain |
| AU2326097A (en) | 1996-03-13 | 1997-10-01 | Zymogenetics Inc. | Cytokine-receptor expressed in testis cells |
| WO1997047742A1 (en) | 1996-06-12 | 1997-12-18 | Smithkline Beecham Corporation | Hr-1 receptor |
| EP0812913A3 (en) * | 1996-06-12 | 1999-08-04 | Smithkline Beecham Corporation | HR-1 receptor, a receptor of the cytokine receptors family |
| AU6175696A (en) | 1996-06-12 | 1998-01-07 | Human Genome Sciences, Inc. | Hr-1 receptor |
| WO1998010638A1 (en) | 1996-09-10 | 1998-03-19 | Amrad Operations Pty. Ltd. | Therapeutic molecules |
| GB9625899D0 (en) | 1996-12-13 | 1997-01-29 | Glaxo Group Ltd | Substances and their uses |
| CN1572325A (zh) | 1997-01-10 | 2005-02-02 | 拜奥根Idec马萨诸塞公司 | 用抗cd40l化合物治疗狼疮性肾炎 |
| US6387615B2 (en) * | 1997-04-11 | 2002-05-14 | Isis Innovation Limited | Methods and materials for the diagnosis or prognosis of asthma |
| GB9723553D0 (en) | 1997-11-07 | 1998-01-07 | Duff Gordon W | Prediction of the risk of chronic obstructive airway disease |
| WO1999029888A1 (en) | 1997-12-05 | 1999-06-17 | The Scripps Research Institute | Humanization of murine antibody |
| US7507706B1 (en) | 1998-12-14 | 2009-03-24 | Genetics Institute, Llc | Cytokine receptor chain |
| WO2000078336A1 (en) | 1999-06-21 | 2000-12-28 | Genetics Institute, Inc. | Treatment of fibrosis by antagonism of il-13 and il-13 receptor chains |
| WO2001023410A2 (en) | 1999-09-28 | 2001-04-05 | Genaissance Pharmaceuticals, Inc. | Drug target isogenes: polymorphisms in the interleukin 13 gene |
| JP2003511019A (ja) | 1999-10-06 | 2003-03-25 | ザ ペン ステート リサーチ ファウンデーション | Ｉｌ１３変異体 |
| US6846486B1 (en) | 2000-02-24 | 2005-01-25 | Advanced Biotherapy Concepts, Inc. | Method of treating allergy by administering an anti-histamine antibody |
| PT2990420T (pt) | 2000-05-26 | 2017-03-16 | Immunex Corp | Uso de anticorpos de recetor de interleucina-4 e composições dos mesmos |
-
1999
- 1999-12-13 US US09/868,123 patent/US7507706B1/en not_active Expired - Fee Related
- 1999-12-13 EP EP99966166A patent/EP1141286B1/en not_active Revoked
- 1999-12-13 CN CN99815591A patent/CN1352686A/zh active Pending
- 1999-12-13 ES ES99966166T patent/ES2277460T3/es not_active Expired - Lifetime
- 1999-12-13 JP JP2000588352A patent/JP5519087B2/ja not_active Expired - Fee Related
- 1999-12-13 BR BR9916209-1A patent/BR9916209A/pt not_active Application Discontinuation
- 1999-12-13 WO PCT/US1999/029493 patent/WO2000036103A1/en not_active Ceased
- 1999-12-13 DK DK99966166T patent/DK1141286T3/da active
- 1999-12-13 DE DE69933696T patent/DE69933696T2/de not_active Revoked
- 1999-12-13 MX MXPA01006006A patent/MXPA01006006A/es not_active IP Right Cessation
- 1999-12-13 CA CA2356779A patent/CA2356779C/en not_active Expired - Fee Related
- 1999-12-13 CN CN201410767170.2A patent/CN104611339A/zh active Pending
- 1999-12-13 PT PT99966166T patent/PT1141286E/pt unknown
- 1999-12-13 NZ NZ512942A patent/NZ512942A/xx not_active IP Right Cessation
- 1999-12-13 AT AT99966166T patent/ATE342976T1/de active
- 1999-12-13 AU AU21775/00A patent/AU780031B2/en not_active Ceased
-
2007
- 2007-01-17 CY CY20071100068T patent/CY1107657T1/el unknown
-
2010
- 2010-04-20 JP JP2010097430A patent/JP2010263889A/ja active Pending
-
2014
- 2014-02-13 JP JP2014025113A patent/JP2014113165A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2356779A1 (en) | Cytokine receptor chain | |
| JP4938957B2 (ja) | Ｃｄ３０またはｃｄ３０ｌのアンタゴニストを使用する自己免疫および慢性炎症性状態の処置法 | |
| JP2001511347A5 (enExample) | ||
| JP2004500037A5 (enExample) | ||
| JP2003533488A5 (enExample) | ||
| US6084069A (en) | Autotaxin: motility stimulating protein useful in cancer diagnosis and therapy | |
| JP2003521916A (ja) | イヌのアレルギー治療用の組換えキメラ抗−ＩｇＥモノクローナル抗体 | |
| JP2004526413A (ja) | 可溶性ｉｌ−ｔｉｆ／ｉｌ−２２レセプターまたはｉｌ−ｔｉｆ／ｉｌ−２２に結合する結合タンパク質をコードする単離された核酸分子、およびその使用 | |
| AU2241995A (en) | Pharmaceutical formulations for treating japanese cedar pollen allergy | |
| JP3316535B2 (ja) | ダニアレルゲンの改変体およびその製造法 | |
| EP0463059B1 (en) | Allergenic proteins from ragweed and uses therefor | |
| KR20230041795A (ko) | 인간화 항-IL-4Rα 단일도메인 항체 및 이의 용도 | |
| CN100469789C (zh) | 尘螨属2组的变应原性蛋白质的变体 | |
| US5776761A (en) | Nucleic acids encoding allergenic proteins from ragweed | |
| US20050221433A1 (en) | IL-18 specific polypeptides and therapeutic uses thereof | |
| CN1291106A (zh) | 新型免疫疾病预防剂/治疗剂 | |
| JP4745237B2 (ja) | パリエタリアジュダイカの主要アレルゲンの低アレルギー性変異体、その使用およびそれらを含む組成物 | |
| JP2000511418A (ja) | ヒトインターロイキン―１ｊおよびそのアンタゴニスト | |
| JP2004533841A5 (enExample) | ||
| JP2002522021A5 (enExample) | ||
| CN119954928B (zh) | Il-21突变体、含其的融合蛋白、核酸、重组表达载体、宿主细胞及其制备方法和用途 | |
| CN119954930B (zh) | Il-21突变体、含其的融合蛋白、核酸、重组表达载体、宿主细胞及其制备方法和用途 | |
| US5242807A (en) | Recombinant gene encoding human Charcot-Leyden crystal protein | |
| JPH08176192A (ja) | ヒノキ花粉アレルゲン | |
| CN119954929A (zh) | Il-21突变体、含其的融合蛋白、核酸、重组表达载体、宿主细胞及其制备方法和用途 |